The preliminary data demonstrate potent activity of Ruxolitinib in steroid-refractory aGvHD.
In this phase 2 trial the efficacy of Ruxolitinib and best available treatment (BAT) versus
BAT in steroid-refractory acute GvHD in approximately 12 transplantation centers in Germany
will be compared. The response by monitoring the clinical GvHD grade, requirement of
alternative GvHD active agents and serum levels of pro-inflammatory cytokines will be
determined.